Home›Trial›NCT07290257
NCT07290257Phase 4RECRUITING

Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)

Study Summary

The key objectives of this low-intervention clinical study are to evaluate tolerability, long-term safety and long-term efficacy for patients with Alagille syndrome (ALGS) who are prescribed Livmarli.

Conditions
Alagille Syndrome
Interventions / Drugs
Livmarli Oral Product
View on ClinicalTrials.gov ↗
Sponsor
MIRM
Mirum Pharmaceuticals
Liver Disease
D36/100
Study Details
Enrollment100 participants
Primary Completion—
Lead SponsorMirum Pharmaceuticals, Inc.
Data Retrieved2026-04-11 04:21:18.704594+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

This trial phase represents an early or specialized stage of clinical development.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 100 participants
Sponsor Catalyst Profile

Mirum Pharmaceuticals (MIRM) is the sponsoring company for this trial. BiotechSign currently grades this company D (36/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

MIRM Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.